Fresenius Completes Acquisition of Biopharma Subsidiary mAbxience for Up to €750 Million

Fresenius has fully acquired its biopharma subsidiary mAbxience for up to €750 million, enhancing its business portfolio. A condition applies to €50 million of the deal.